Moving on to greener pastures.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Headquarters in Overland Park Kansas have look like a morgue for several years. Perhaps now somebody can purchase the concentration camp looking buildings and build a good headquarters for another big conglomerate like APPLE who is looking for a second HQ
DOWN SHE GOES......
LONG TERM HOLD...... LOVE ISRG...
Our day is coming. Just have patience and wait the Patients are coming SHORTLY.
Great restructuring move by MannKind. The keep making the right adjustments to get cash and remove short term debt. No issue on my part with this move.
http://ih.advfn.com/p.php?pid=nmona&article=76919974
The retail shareholders have now power over how the deal transacts. We are just along for the ride at this point but sadly we got screwed and don’t be surprised to see the deal challenged by a activist investor and several class action attorneys.
The rights offering back in January was to prevent Albertson’s parent company from coming in and buying shares on the open market while Standley negotiated his sweetheart deal.
Shareholders screwed.
I only hope a activist steps in and stirs the pot as Standley screwed the shareholders for his own benefit.
The deal is a crappy one for shareholders.
FRAUD and CLASS ACTION lawsuit ahead. They knew back in January what they were doing and didn't disclose when they filed the poison pill documents.
Who would the potential suitor be for the company ?
You may be correct as Masa Son is a madman and Sprint needs to be sold to TMUS. Sadly I live in Overland Park, Kansas. Drive by the Sprint HQ everyday and its sad to see that campus so under utilized.
MAZOR is ready for the next leg up to $65.00.
Yep I think that Dr. Kendall is the real deal and some can spread some FUD around but look at the blue print that Mike Castagna and the the Board of directors of MannKind have executed in the less than 24 months that Mike has been with the company. Mike has been the President / CEO even less than that time frame.
I have said for many years on this board that the future is very brite for MannKind. Sure there has been many missteps over the last 5 years with MannKind. Some of that goes back before that time frame. Al Mann knew what he had but didn’t have the right team or advisors around him later in his life.
The debacle trying to get FDA approval and going back to the Christmas Massacre created by Martin Shrekli. He should be in jail for the manipulation of the FDA and the games he played shorting MannKind. FDA commissioner Hamburg should be in Jail too.
The Trend has turned positive and script counts will soon show that Upward Trend. We will see the momentum before the end of 2018. Social media is not learning about Afrezza. It took a while and fortunately MannKind has had a few dedicated shareholders who keep MannKind in front of the public.
Now users are talking about Afrezza and posting about it on all types of social media.
Yep It’s good to be a MannKind long these days. Confidence allowed many of us to add shares at the very bargain basement prices over the last 24 months. Perhaps we were crazy to buy more shares or maybe some of us had to sell the high dollar shares they owned to capitalize on nice gains on other capital gains or holdings in their portfolio. As painful as it was I did that in 2016 and never looked back as I reinvested back into MannKind after the 35 days of being with out MannKind shares.
The moral of the story is to be a disciplined investor with never having only one position but many different ones. A stock like MannKind should be a piece of your portfolio and not the only thing in it.
Never risk more capital than you can afford to lose and make sure you are investing in a position vs being a gambler. Do your research and due diligence.
Good luck to all of the long believers who stuck it out as our day is coming SHORTLY.
Heico seems to only go in one direction. In their space who would be a company hungry enough to buy Heico out?
BA or ?
Dr. Kendall has a great CV in Diabetes.
David M. Kendall, MD, is the Chief Medical Officer for MannKind Corporation. In this role, he is responsible for leading MannKind’s scientific research, clinical development, regulatory, and medical affairs activity.
Dr. Kendall’s career includes over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy.
Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and led all medical affairs activities and guided research and development strategy across multiple geographies.
During this time, Dr. Kendall worked to re-establish Lilly Diabetes as a world class medical organization — and added to his extensive experience with both injected and mealtime insulins, as well as devices and continuous glucose monitors.
Prior to Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities.
Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals.
Dr. Kendall received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College.
-----------Lets See prior to being hired by MannKind he joined Eli Lilly as a Fellow. ------------------------------
David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly
Kendall will serve as senior medical advisor for Lilly Diabetes in advocacy, science and medical communities
INDIANAPOLIS, May 18, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that David M. Kendall, M.D., currently chief scientific and medical officer of the American Diabetes Association, has been named distinguished medical fellow for Lilly. He will transition from his current role in late-July.
In his new role, Kendall will serve as a senior medical advisor for Lilly Diabetes in advocacy and clinical science communities and as a representative to the professional medical community. In addition, he will help provide scientific direction for Lilly in diabetes discovery and clinical development. Other key responsibilities will include the support of Lilly's medical education efforts and diabetes healthcare evaluation programs.
"David brings a critical external view, including the insights he gained while at the American Diabetes Association," said Enrique Conterno, president of Lilly Diabetes. "We are working hard to gain leadership in diabetes care, and that leadership must start with an understanding of the needs of patients and health care providers."
Kendall will report to Robert Heine, M.D., vice president medical affairs, Lilly Diabetes.
"With his background as a clinician, researcher and diabetes advocate, David is the ideal candidate for this position," said Heine. "His focus, passion and understanding of diabetes care will enable us to create ever better solutions for people living with diabetes."
Yep! Kendall has the credential for the Position for CMO.
Amazing nobody is following this stock. I bought some shares back in early January based on a broker I have known for 20 + Years. I will watch and see what happens in 2018 with IDTI since I don’t know much about their technology other than what is on their web page.
They have many applications in all areas of TECH.
https://www.idt.com/
CUIN2 don’t know enough about this company other than the link you sent me. They seem to be doing in your face marketing on their perceived attributes.
So I can’t render any opinion other than my own investment in CRM for my business has been a failure of implementation and we were using the Microsoft Great Plains CRM platform.
So if he has a deal with Oracle than maybe its going to be a winner but software is a very tough market with some huge players especially in the CRM business.
Had to answer you on this board as I am not a paid member of IHUB so I could not just hit reply back to you.
Lol.... sure you want it to go up. It should because you will it going up. But downwards it goes. Money is easy come easy go in the market.
Heck I am going to wait until it hits .50 and buy back in again.
Lol...... Yep you know it. Milk it for all the cash he can get and blow and go to the next opportunity.
Heck he probably has his resume out already.
Have to agree Friend. Anybody going to listen to Leerink Partners Global Healthcare Conference on Thursday AM.
Hansel and Gretel Might have dropped some breadcrumbs on the way to this conference.
Deerfield still holds debt /notes of the company. They are very much invested
Like Hansel and Gretel they have drop breadcrumbs along the way interesting call tomorrow.
Leerink Partners Global Healthcare Conference
February 15, 2018 at 10:30 AM ET
It’s much easier to ignore the trend on a position like this and go with the flow.
Outed. Oh my
This comment is what you don’t understand. He has the contacts and the relationships in the entire industry. In the US, and Worldwide.
The new standard of treatment care will be based on Afrezza and ditching the pump. SAY PARADIGM Shift.
MannKind will hit stride in 2018/2019
He has He is done work and research for every single drug company involved in the diabetes space.
He has produced over 125 research papers dealing with insulin and metabolic issues.
sid vicious said:
“What will lift Mannkind is when endos and insurance companies embrace Afrezza. And after 3 years of being on the market and having ~10% recognition from diabetics, I'd say the company has a tough road to navigate”
Kendall is a know researcher, Dr., and understands diabetes. He is considered a top thought leader. He has been called on by all different companies the diabetes space to do research.
Thought it was interesting that David Kendall was actually somewhat involved with Mannkind in the past - receiving funding for his research.
www.medscape.org/viewarticle/706179_transcript
Where Do Incretin-Based Therapies Fit in the Diabetes/Obesity Story?
Authors:
David M. Kendall, MD
Faculty and Disclosures
Medical Director and Chief of Clinical and Professional Services, International Diabetes Center, Associate Professor of Medicine (Clinical), University of Minnesota, Minneapolis, Minnesota
Disclosure: David M. Kendall, MD, reports that he has received research grant support from Abbott Laboratories, Dexcom™ Inc, LifeScan Inc, MannKind Corporation, Medtronic Inc, Novo Nordisk A/S, and ResMed; consultant/scientific and clinical advisory board honoraria from CV Therapeutics Inc, Daiichi-Sankyo Co. Limited, HealthPartners, and Takeda Pharmaceuticals North America Inc
---
DR. BUSE: It's now my pleasure to introduce Dr. David Kendall. I gave you his titles et cetera a few moments ago.
He'll be talking about incretin-based therapies and where they fit into the diabetes obesity story. David is arguably, I believe at least, the premiere lecturer in clinical diabetes management. And it's going to be a great talk. You're in for a treat. David, welcome.
--
A very good hire respected by peers with LOTS of connections in Diabetes space and other pharma companies.
Read more: http://mnkd.proboards.com/thread/9525/david-kendall-mannkind-medical-officer?page=12#ixzz571kgsjZv
What milestones says this company made since 2014? None. There are no closer to getting FDA or CE approval today and they were in 2014. All they do is burn cash.
How many have they sold? I believe one or two of them were sold to Hospital’s to help them do the testing. They did not get full price for the equipment.
Lol..........It will never come in they cannot monetize the product.
Yes it’s going to fail because they are going to run out of money before they get FDA or CE approval. I have done a poor job of bringing the product to market.
Somebody will pick up the pieces cheap and perhaps bring it to market it will not be the titan folks
Lol!
I guess we will have to wait-and-see.
But over the last 24 months CEO Michael Castagna has worked hard to turn this company around.
He has checked off all the boxes one at a time turning this company around.
He has built a great team around himself,
Dr. Kendall perhaps the most important piece to finish the task of monetizing Afrezza.
Why does a high ranking vice President at Eli Lilly leave his job for a struggling troubled company that is 5% the size of Eli Lily.
Kendall knows what’s ahead.
Perhaps there is even some type of international partnership with Eli Lily!
I don’t know and you don’t know what there is, but something good is waiting to happen.
Kendall has standing in his field as a diabetes specialist. He has worked at all different levels. Dr., researcher, ADA VP., and lastly VP at Eli Lilly.
He knows all the thought leaders in the field. Doctors, PBM., Insurance companies. He has testified at the FDA. He has been involved in bringing new drugs to market. Additionally launching drugs Worldwide.
He did not join MannKind to fail. He evidently knows what is ahead in properly monetizing Afrezza. You can go to pro boards and read the extensive threads about his background.
His comment about joining MannKind is very exciting for many of us long shareholders.
“The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes," said Dr. Kendall. "Afrezza is the only inhaled fast-acting mealtime insulin on the market, and offers the right patients a flexible, safe, and effective treatment option. I'm thrilled to join MannKind, and look forward to being part of a company that has the potential to transform the lives of so many people that are living with diabetes."
You must not have read the thread I was engaged with him on.
Large companies will let TITXF die and then pick the bones in the bankruptcy court.
No as they have their own research and development and you can be sure that Intuitive has their own proprietary Patents that cover anything they produce.
Can TITXF sue ISRG? Probably not as that takes a lot of cash and will drain the limit cash this company has.
Never will make it to market place.
Both companies seem to have a limited potential and they both will run out of cash shortly.
Trans was lucky enough to get approved but has no sales and their competitors will let it fade away and die.
TITXF will bleed itself to death. Maybe one of the big boys will pick the bones in bankruptcy for some tech they already don’t have on their products.
SS titanic. You’re better get your life boat this thing is sinking fast without a sales partner
Meet David Kendall, MD
diabetesstopshere.org/2010/11/03/meet-david-kendall-md/
Posted on November 3, 2010 by American Diabetes Association
Meet David Kendall, MD, Chief Scientific and Medical Officer at the American Diabetes Association. David dreams big – from cures for diabetes to the Champions Tour in golf.
David leads the Association’s scientific and medical group, including medical affairs, professional education, publications and research. This group provides scientific and medical input and expertise support for every other function of the Association, such as advocacy, development and marketing and communications.
Sounds like a pretty big responsibility, but David has the background and the skills to step up to the task. So I sat down to chat with him about what brought him to diabetes.
Why did you become an endocrinologist?
The short answer is $10 an hour – but let me explain:
I took a year off between college and medical school and needed to find work. Through a connection at the University of Minnesota, I found a research job with a group that worked in diabetes and transplantation. At that point, the job appealed to me because it paid $10 an hour. Honestly, I thought it was great pay for a recent college graduate, and it involved the science I enjoyed, so I started working there.
I kept that job all through medical school and ended up joining the group as a resident, fellow and ultimately as faculty doing similar research work.
What kind of research was it?
Originally I was in the clinical research center (diabetes and metabolism), then I focused more on the pancreas and kidney transplant program work. I was always interested in what makes biochemistry clinical (how hormones and chemical signals work in the body – or in some cases, DON’T work in the body).
When I combined that with having been in diabetes research since the year prior to medical school, it was an easy choice for me to continue into endocrinology.
I’ve heard you also have some personal connections to diabetes – care to share those?
Despite the “good money” in diabetes research (yes, that’s sarcasm!), having a personal connection to disease was also key for me. An aunt of mine was diagnosed with type 1 diabetes in the 1950s, so I knew about type 1 from my mother who lived with my aunt until she passed away at an early age.
My grandfather on my mother’s side also had diabetes (he was also a physician) and his diabetes was complicated by heart disease. So in a sense both type 1 and type 2 diabetes were familiar to me.
Having a personal connection to the disease is not what got me into diabetes, but it is what kept me there.
What do you wish people knew/thought more about when it comes to thinking about their health care provider?
My favorite perspective on health care is that it’s an elective procedure. You can do as much or as little as you wish. You may have to do the bare minimum to function, but the more you do, the more you’ll benefit. You can get advice from your health care team, but whatever you choose to do with it is personal choice. It is important to have a continuous dialogue with your health care provider and work to overcome some of the challenges. I don’t think people choose to do the wrong thing, I think it’s really more that the advice must be better suited to that individual. If it’s not working well, both patient and provider team should ask “what else could we try?”
What do you wish health care providers knew/thought more about when it comes to their patients?
Same thing! What they are giving is advice – not commands or specific instructions. So it’s important to aim for the best advice possible for that individual.
I also think that every health care provider should recognize that humility is the greatest attribute they can have. This is an essential part of medical care. We have to understand how little we actually DO know – both about the individuals we see and the individual diseases we treat. We also have to be willing to admit when we don’t have full understanding and do our best to get as much information as possible (even in the absence of perfect information).
I’ve been reading Atul Gawande’s book Better: A Surgeon’s Notes on Performance and really liked this piece of advice he gives; “Ask an unscripted question. Ours is a job of talking to strangers. Why not learn something about them?” I used to do that in clinic, and still do, and find it’s what I remember best.
You’ve been in the diabetes field since long before I was diagnosed. What changes you have seen?
When I first started in the diabetes field, people looked at me like I was from Mars. “Why would you do that?” they asked. “There’s nothing new, nothing changing in diabetes.”
Really?
Yeah, but all we really had at the time was animal insulin and first generation sulfonylureas. That’s it – so just about everything we use today to treat diabetes has been introduced since the 1990s (and, consequently, virtually everything I learned as a fellow is obsolete).
The last 15 years have seen a remarkable expansion in the available treatments for diabetes. Even blood glucose monitoring was controversial then. There were arguments for and against sharing information about blood glucose because they thought people with diabetes wouldn’t have the skills to self-manage the disease. At that point it was the physician’s job to manage diabetes. But now physicians and other health care providers don’t really manage diabetes. Patients manage diabetes with the guidance of their health care team.
People with diabetes now have a nearly normal lifespan. The management (although arguably complex) is infinitely better than when my aunt and grandfather sharpened their needles before injections and urinated in a cup to determine their glucose levels. Now we have remarkable tools – but how do we provide better care?
I think that’s what we have coming up in the next decade. Everything from drug development to care delivery has to be better integrated. You can’t just hand someone a tool and hope they know how to use it. Insulin pumps and CGMs are useless unless someone knows how to use them – it’s like giving someone a Ferrari in rush hour – it’s an incredible remarkable improvement that can’t be used to its full potential.
If you could tell the world one thing about diabetes, what would it be?
That it’s important to take a step back periodically and appreciate how remarkable the progress has been in the last two decades.
We’re approaching the 100th anniversary of the discovery of insulin, but most of that time, progress was imperceptible. In the last 10 to 20 years we have seen major advances. Although it can still be frustrating, people should marvel at the progress that’s been made, and those who live with diabetes should have every expectation that the pace of discovery should be as great or greater than that in the past 10 to 20 years.
Read more: http://mnkd.proboards.com/thread/9525/david-kendall-mannkind-medical-officer?page=8#ixzz56lSMd1kJ
Dr. Kendall has been involved over his career in at least 125 different scientific publications regarding diabetes. Below is the link to the publications.
You can only read the abstract’s because the documents are behind a paid firewall. But he has had extensive research and publication over his career
www.researchgate.net/scientific-contributions/38210957_David_M_Kendall
David M Kendall's scientific contributions
while affiliated with Eli Lilly and Company (Indianapolis, United States) and other places
Publications (125)
If you don’t think that the fuse has been lit, to set off the bomb then you better sell your stock today.
All I can say is Mike you magnificent CEO, you found the holy
Read more: http://mnkd.proboards.com/thread/9525/david-kendall-mannkind-medical-officer?page=8#ixzz56lS1ViIW
It will be interesting how David Kliff spins David Kendall’s hiring. Loved him in 2011.
Interesting view from 2011 A Major Loss for the ADA, A Major Gain for Lilly
5/11/2011 @diabetic_invstr
A Major Loss for the ADA, A Major Gain for Lilly
Posted on May 18, 2011 by Diabetic Investor
(Excerpt)
This afternoon Lilly (NYSE:LLY) announced that Dr. David Kendall, currently the chief scientific and medical officer of the American Diabetes Association (ADA), has been named distinguished medical fellow for Lilly. According to the Lilly press release; “In his new role, Kendall will serve as a senior medical advisor for Lilly Diabetes in advocacy and clinical science communities and as a representative to the professional medical community. In addition, he will help provide scientific direction for Lilly in diabetes discovery and clinical development. Other key responsibilities will include the support of Lilly's medical education efforts and diabetes healthcare evaluation . . .
https://diabeticinvestor.com/a-major-loss-for-the-ada-a-major-gain-for-lilly/